ArticleAdvanced biomedical research2025
Combination of EGCG and BH3 Mimetic Inhibitor Enhances Apoptosis of MCF-7 and MDA-MB-231 Cancer Cells.
Article in Advanced biomedical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Elevated levels of myeloid cell leukemia 1 (Mcl-1) have been shown to counteract the proapoptotic effects of ABT-737, thereby promoting cell survival and contributing to treatment resistance in tumors. This study aimed to evaluate the effect of epigallocatechin gallate (EGCG) on the expression of Mcl-1 and the sensitivity of MDA-MB-231 and MCF-7 breast cancer cells to ABT-737. Materials and Methods: Cell toxicity was assessed through the implementation of the MTT assay. To evaluate the impact of treatments on cell proliferation, both the cell growth assay and the colony formation assay were employed. The mRNA levels of Results: Combined EGCG and ABT-737 significantly reduced IC Conclusions: EGCG has been shown to possess antitumor properties in breast cancer cells. Moreover, EGCG has the potential to enhance the apoptotic effects of ABT-737 by suppressing the expression of Mcl-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.